[225+ Pages Research Report] According to the recent research report; the global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market in 2020 was approximately USD 5,150.4 Million. The market is expected to surge at a CAGR of 21.4% and is anticipated to surpass USD 16,487.4 Million by 2026. Top market players in the market are Sutro Biopharma, Malin Corporation, Eureka Therapeutics, Transposagen Biopharmaceuticals, firstVentury Equity, Five Prime Therapeutics, Bluebird Bio, Dana-Farber Cancer Institute, Deerfield Partners and others.

New York, NY, May 07, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “B-Cell Maturation Antigen (BCMA) Targeted Therapies Market by Product Type (CAR-T cell, Antibody Drug Conjugates, and Bispecific Antibodies), By Indication (Multiple Myeloma and Acute Lymphoblastic Leukemia) By End User (Hospitals and Cancer Research Institute) By Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026”.

“According to the research report, the global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market was estimated at USD 5,150.4 Million in 2020 and is expected to reach USD 16,487.4 Million by 2026. The global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market is expected to grow at a compound annual growth rate (CAGR) of 21.4% from 2020 to 2026”.

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Key Market Insights Overview

Targeted therapy for B-cell maturation antigen (BCMA) (BCMA-TT) has emerged as a potential treatment for Multiple Myeloma (MM). bispecific antibody constructs, Antibody-drug conjugates (ADCs), containing chimeric antigen receptor (CAR)-modified T-cell therapy, BiTE (bispecific T-cell engager) immuno-oncology therapies, and are the three most popular treatment modalities for targeting BCMA.

Blenrep, a GSK antibody-drug conjugate, was the first FDA-approved anti-BCMA treatment for highly refractory Multiple Myeloma in August 2020. (MM). The FDA has now approved a second drug that targets this antigen.

Request Your Free Sample Report of B-Cell Maturation Antigen (BCMA) Targeted Therapies Market @ https://www.fnfresearch.com/sample/global-b-cell-maturation-antigen-bcma-targeted-therapies-market

(The free sample of this report is readily available on request).

Our Free Sample Report Includes:

• 2020 Updated Report Introduction, Overview, and In-depth industry analysis

• COVID-19 Pandemic Outbreak Impact Analysis Included

• 225+ Pages Research Report (Inclusion of Updated Research)

• Provide Chapter-wise guidance on Request

• 2020 Updated Regional Analysis with Graphical Representation of Size, Share & Trends

• Includes Updated List of table & figures

• Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis

• Facts and Factors research methodology

(Note: The sample of this report is updated with COVID-19 impact analysis before delivery)

Key Questions Answered in this Report

1) What was the pre and post-business impact of COVID-19 on the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

2) What is the market size, share of the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

3) Who are the top market players in B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

4) What will be the future market of the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

Key Offerings:

• Market Size & Forecast by Revenue | 2020−2026

• Market Dynamics – Leading trends, growth drivers, restraints, and investment opportunities

• Market Segmentation – A detailed analysis by product, by types, end-user, applications, segments, and geography

• Competitive Landscape – Top key vendors and other prominent vendors

Inquire more about this report before purchase @ https://www.fnfresearch.com/inquiry/global-b-cell-maturation-antigen-bcma-targeted-therapies-market

(You may enquire a report quote OR available discount offers to our sales team before purchase.)

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Industry Major Market Players

• Poseida Therapeutics Inc.

• Autolus Ltd.

• Juno Therapeutics

• Malin Corporation

• Eureka Therapeutics

• Transposagen Biopharmaceuticals

• Sutro Biopharma

• Onyx Pharmaceuticals

• GlaxoSmithKline plc

• Novartis AG

• Gilead Sciences. Inc.

• Amgen Inc.

• Affimed N.V

• firstVentury Equity

• Five Prime Therapeutics

• Bluebird Bio

• Deerfield Partners

• Celgene Corporation

• Dana-Farber Cancer Institute others.

To know an additional revised 2020 list of market players, request a sample report: https://www.fnfresearch.com/sample/global-b-cell-maturation-antigen-bcma-targeted-therapies-market

Market Dynamics

The cell surface protein BCMA is expressed on malignant plasma cells. In patients with multiple myeloma, expression profiles of BAFF-R and TACI are lower than those of B-Cell maturation antigen. Furthermore, these antigens are rarely found in malignant plasma cells, implying that B-Cell maturation antigen is a preferred targeting antigen over others. With progression from usual Monoclonal Gammopathy of Undetermined Significance to smoldering many myeloma (SMM) to active numerous myeloma, the expression of BCMA steadily increases. Since B-Cell maturation antigen cells have a very limited expression pattern and are not expressed in regular human tissues, they have a special expression profile. As a result, B-Cell maturation antigen -target therapy has gained traction in cancer care and will be the treatment of choice, especially for multiple myeloma. Myeloma cell survival is regulated by BCMA's co-immunoprecipitation property with the master transcription factor (IRF-4). Based on product class, B-Cell maturation antigen targeted therapies actively include three main forms of immunotherapies: CAR T Cells, antibody-drug conjugates, and bispecific antibodies.

Multiple myeloma (MM) is a clonal plasma cell malignant neoplasm that develops in the bone marrow's soft, spongy tissue. Plasma cells are an important component of the immune system that aids in the battle against infections and other diseases. Low blood counts, renal dysfunction, hypercalcemia, immune suppression, monoclonal gammopathy, and anemia are all symptoms of multiple myeloma, cancer caused by malignant plasma cells. In addition, multiple myeloma is also an incurable condition. According to the American Cancer Society, an estimated 30,280 adults (17,490 men and 12,790 women) will be diagnosed with multiple myeloma in the United States in 2017, with 12,590 deaths (6,660 men and 5,930 women) due to the disease. Multiple myeloma accounts for 8.2% of all blood cancers in Africa, according to the National Center for Biotechnology Information.

Directly Purchase a copy of the report with TOC @ https://www.fnfresearch.com/buynow/su/global-b-cell-maturation-antigen-bcma-targeted-therapies-market

Growing Investment by Market Players

Players in the market are investing heavily in the research and production of new multiple myeloma therapies. Chimeric antigen receptor T cells, antibody-drug conjugates, and Bi-specific antibodies are examples of these therapies. GlaxoSmithKline Plc. (GSK2857916), for example, is working on an antibody-drug conjugate for relapsed/refractory multiple myeloma and other advanced hematologic malignancies that express BCMA. The demand for B-cell maturation Antigen (BCMA) targeted therapies is expected to develop due to a strong pipeline of therapies for the treatment of multiple myeloma.

Chemotherapy and radiation therapy patients are at a high risk of cancer recurrence when they gain resistance to these treatments. There are currently no treatment options for patients with recurrent cancer, so the BCMA targeted therapies represent a significant advancement in the treatment of relapsed or refractory multiple myeloma, where conventional treatment modalities have proven to be ineffective.

Request Customized Copy of Report @ https://www.fnfresearch.com/customization/global-b-cell-maturation-antigen-bcma-targeted-therapies-market

(We customize your report according to your research need. Ask our sales team for report customization.)

North America is projected to Dominate Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth

North America led the global B-Cell Maturation Antigen (BCMA) targeted therapies market in 2020. The United States held the majority share in North America -Cell Maturation Antigen (BCMA) targeted therapies market owing to ongoing development in the region paired with the presence of key market players. The Asia Pacific is expected to the fastest-growing region for the global B-Cell Maturation Antigen (BCMA) targeted therapies market owing to increasing demand in China, and India.

Browse the full “B-Cell Maturation Antigen (BCMA) Targeted Therapies Market by Product Type (CAR-T cell, Antibody Drug Conjugates and Bispecific Antibodies), By Indication (Multiple Myeloma and Acute Lymphoblastic Leukemia) By End User (Hospitals and Cancer Research Institute) By Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026” report at https://www.fnfresearch.com/global-b-cell-maturation-antigen-bcma-targeted-therapies-market

Impact Analysis of COVID-19 Pandemic on Businesses: Know Short Term and Long Term Impact

Most of the businesses are facing a growing litany of business-critical concerns related to the coronavirus outbreak, including supply chain disruptions, a risk of a recession, and a potential drop in consumer spending. All these scenarios will play out differently across various regions and industries, making accurate and timely market research more essential than ever.

We at Facts and Factors (http://www.fnfresearch.com ) understand how difficult it is for you to plan, strategize, or make business decisions, and as such, we have your back to support you in these uncertain times with our research insights. Our team of consultants, analysts, and experts has developed an analytical model tool for markets that helps us to assess the impact of the virus more effectively on the industrial markets. We are further implementing these insights into our reports for a better understanding of our clients.

Request COVID-19 Impact Analysis on Businesses: https://www.fnfresearch.com/sample/global-b-cell-maturation-antigen-bcma-targeted-therapies-market

Frequently Asked Questions

What are the key factors driving B-Cell Maturation Antigen (BCMA) Targeted Therapies market expansions?

Players in the market are investing heavily in the research and production of new multiple myeloma therapies. Chimeric antigen receptor T cells, antibody-drug conjugates, and Bi-specific antibodies are examples of these therapies. GlaxoSmithKline Plc. (GSK2857916), for example, is working on an antibody-drug conjugate for relapsed/refractory multiple myeloma and other advanced hematologic malignancies that express BCMA. The demand for B-cell maturation Antigen (BCMA) targeted therapies is expected to develop due to a strong pipeline of therapies for the treatment of multiple myeloma.

What will be the value of the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market during 2020- 2026?

According to Facts and Factors, global demand for the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market is expected to generate revenue of around USD 16,487.4 million by end of 2026, growing at a CAGR of around 21.4% between 2021 and 2026.

Which region will make notable contributions towards global B-Cell Maturation Antigen (BCMA) Targeted Therapies market revenue?

According to our estimates, North America accounted for the bulk of market share owing to the presence of noticeable market participants coupled with ongoing investment in research and development. US, China, India, and Germany are the major market to watch out for in the analysis period.

The Global B-Cell Maturation Antigen (BCMA) targeted therapies market is segmented as follows:

By Product Type:

• CAR-T Cell

• Antibody Drug Conjugates

• Bispecific Antibodies

By Indication:

• Multiple Myeloma

• Acute Lymphoblastic Leukemia

By End User:

• Hospitals

• Cancer Research Institute

KEY REPORT POINTERS & HIGHLIGHTS:

• Statistically Validated Analysis of Historical, Current, and Projected Industry Trends with Authenticated Market Sizes Information and Data in terms of Value and Volume, wherever applicable

• Direct and Indirect Factors that Impacted the Industry as well Projected Rationales expected to affect the industry going forward

• Micro, Meso, Macro, and In-Depth Analysis of Technically relevant and Commercially viable Segments and Sub-segments of the Market

• Historical and Projected Company / Vendor / OEM / Supplier Market Shares, Competitive Landscape, and Player Positioning Data

• Historical and Current Demand (Consumption) and Supply (Production) Scenarios as well as Projected Supply-Demand Scenario Analysis

• Detailed List of Key Buyers and End-Users (Consumers) analyzed as per Regions and Applications

• Value Chain and Supply Chain Analysis along with Horizontal and Vertical Integration Scenarios

• Manufacturing and Production Cost Structure Analysis including Labor Cost, Raw Material Expenses, and Other Manufacturing Expenses, wherever relevant

• Overview of Key Marketing Strategies and Key Sales Channels Adopted in the Market

About Facts & Factors (FnF Research):

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds.

Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Follow Us LinkedIn: https://www.linkedin.com/company/fnfresearch

Follow Us Twitter: https://twitter.com/fnfresearch

Contact Us:

Facts & Factors

USA: +1-347-989-3985

Email: sales@fnfresearch.com

Web: https://www.fnfresearch.com

Blog: http://fnfnewsblog.com